Loading
USP6 (Ubiquitin carboxyl-terminal hydrolase 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Breast cancer, Hepatocellular carcinoma and 5 more.
Deubiquitinase with an ATP-independent isopeptidase activity, cleaving at the C-terminus of the ubiquitin moiety. Catalyses its own deubiquitination. In vitro, isoform 2, but not isoform 3, shows deubiquitinating activity.
Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes literature 0.78, animal model 0.53, genetic association 0.00, somatic mutation 0.96). IntOGen calls it a driver in 8 cohorts (5 activating, 0 loss-of-function), covering Acute Myeloid Leukaemia, Basal Cell Carcinoma, Invasive Breast Carcinoma, Colorectal Adenocarcinoma, Hepatocellular Carcinoma, Lung Squamous Cell Carcinoma and others.
In plain words · USP6 (Ubiquitin carboxyl-terminal hydrolase 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Breast cancer, Hepatocellular carcinoma and 5 more.
USP6 (Ubiquitin carboxyl-terminal hydrolase 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Breast cancer, Hepatocellular carcinoma and 5 more.
Deubiquitinase with an ATP-independent isopeptidase activity, cleaving at the C-terminus of the ubiquitin moiety. Catalyses its own deubiquitination.
No product in this corpus aims at USP6 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 1992. Earliest sequence paper UniProt cites for the protein: Nakamura et al, Oncogene, 1992, "A novel transcriptional unit of the tre oncogene widely expressed in human cancer cells". Source.
Sources: HGNC HGNC:12629 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P35125 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000129204 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: colorectal cancer 0.59, melanoma 0.56, sarcoma 0.53, skin cancer 0.57, breast cancer 0.51, lung cancer 0.54 (GraphQL API, CC0)); IntOGen USP6 (driver in 8 cohorts (Act 5, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Deubiquitinase with an ATP-independent isopeptidase activity, cleaving at the C-terminus of the ubiquitin moiety. Catalyses its own deubiquitination. In vitro, isoform 2, but not isoform 3, shows deubiquitinating activity. Promotes plasma membrane localisation of ARF6 and selectively regulates ARF6-dependent endocytic protein trafficking. Is able to initiate tumorigenesis by inducing the production of matrix metalloproteinases following NF-kappa-B activation. May act as a GTPase-activating protein for RAB3A. Location: Cell membrane; Cytoplasm; Endosome (UniProt). Locus 17p13.2 (HGNC).
Query for this target: (TITLE:"USP6" OR ABSTRACT:"USP6" OR TITLE:"ubiquitin specific peptidase 6" OR ABSTRACT:"ubiquitin specific peptidase 6" OR TITLE:"Ubiquitin carboxyl-terminal hydrolase 6" OR ABSTRACT:"Ubiquitin carboxyl-terminal hydrolase 6" OR TITLE:"Tre-2" OR ABSTRACT:"Tre-2" OR TITLE:"TRE17" OR ABSTRACT:"TRE17" OR TITLE:"Tre2" OR ABSTRACT:"Tre2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about USP6, not a curated reading list.